免疫生物

最新新闻

• 评级变动
  H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/2/19
• 评级变动
  Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $12
  \u5e02\u573a\u8d44\u8baf · 2026/3/4
• Form 144 | ImmunityBio(IBRX.US) Officer Proposes to Sell 7.66 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2026/3/12
• 评级变动
  Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $5
  \u5e02\u573a\u8d44\u8baf · 2025/12/15
• H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $9
  \u5e02\u573a\u8d44\u8baf · 2026/1/23
• 评级变动
  BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $9
  \u5e02\u573a\u8d44\u8baf · 2026/2/3
• 评级变动
  H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/1/26
• 评级变动
  BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Cuts Target Price to $12
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/3/25
• BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  ImmunityBio (IBRX) Receives a Buy From H.C. Wainwright
  TipRanks · 2026/5/8
• 评级变动
  Jefferies Initiates ImmunityBio(IBRX.US) With Buy Rating, Announces Target Price $9
  \u5e02\u573a\u8d44\u8baf · 2025/12/13
• Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.22 a Share, Vs. FactSet Est of $0.08 Loss
  MT Newswires · 2026/8/4
• 评级变动
  H.C. Wainwright Sticks to Its Buy Rating for ImmunityBio (IBRX)
  TipRanks · 2026/4/30
• 评级变动
  Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $7
  \u5e02\u573a\u8d44\u8baf · 2026/1/20
• 评级变动
  H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/2/24
• 评级变动
  H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/1/20

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。